Madrigal Pharma (MDGL) Misses Q4 EPS by 44c
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($5.68), $0.44 worse than the analyst estimate of ($5.24).
For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Gaxos.ai Inc. (GXAI) Reports Q2 EPS of $0.02
- Marchex (MCHX) Reports In-Line Q2 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
